PreveCeutical Announces Date for Annual General and Special Meeting
PreveCeutical Medical (OTCQB: PRVCF) has scheduled its annual general and special meeting for August 15, 2025. Shareholders will vote on director elections, auditor appointments, and notably, a plan to distribute up to 12 million common shares of BioGene Therapeutics to PreveCeutical shareholders.
The arrangement will result in shareholders owning stakes in two separate companies: BioGene, focusing on Dual Gene Therapy program development, and PreveCeutical, continuing its focus on preventive and curative therapies using organic products. This strategic separation aims to expand both companies' shareholder bases and improve access to capital for research and development.
PreveCeutical Medical (OTCQB: PRVCF) ha fissato la sua assemblea generale annuale e straordinaria per il 15 agosto 2025. Gli azionisti voteranno sull'elezione dei direttori, la nomina dei revisori dei conti e, in particolare, su un piano per distribuire fino a 12 milioni di azioni ordinarie di BioGene Therapeutics agli azionisti di PreveCeutical.
Questa operazione porterà gli azionisti a detenere partecipazioni in due società distinte: BioGene, focalizzata sullo sviluppo del programma di terapia genica duale, e PreveCeutical, che continuerà a concentrarsi su terapie preventive e curative basate su prodotti organici. Questa separazione strategica mira ad ampliare la base di azionisti di entrambe le società e a migliorare l'accesso ai capitali per la ricerca e lo sviluppo.
PreveCeutical Medical (OTCQB: PRVCF) ha programado su junta general anual y extraordinaria para el 15 de agosto de 2025. Los accionistas votarán sobre la elección de directores, la designación de auditores y, en particular, un plan para distribuir hasta 12 millones de acciones comunes de BioGene Therapeutics a los accionistas de PreveCeutical.
Este acuerdo resultará en que los accionistas posean participaciones en dos compañías separadas: BioGene, enfocada en el desarrollo del programa de terapia génica dual, y PreveCeutical, que continuará centrada en terapias preventivas y curativas utilizando productos orgánicos. Esta separación estratégica busca ampliar la base de accionistas de ambas empresas y mejorar el acceso a capital para investigación y desarrollo.
PreveCeutical Medical (OTCQB: PRVCF)는 2025년 8월 15일에 연례 및 특별 주주총회를 예정하고 있습니다. 주주들은 이사 선임, 감사 선임, 그리고 특히 PreveCeutical 주주들에게 BioGene Therapeutics의 1,200만 보통주를 배분하는 계획에 대해 투표할 예정입니다.
이 조치는 주주들이 두 개의 별도 회사에 지분을 보유하게 하는데, BioGene은 이중 유전자 치료 프로그램 개발에 집중하며, PreveCeutical는 유기농 제품을 활용한 예방 및 치료 요법에 계속 주력할 것입니다. 이러한 전략적 분리는 두 회사의 주주 기반을 확대하고 연구 개발을 위한 자본 접근성을 향상시키는 것을 목표로 합니다.
PreveCeutical Medical (OTCQB : PRVCF) a programmé son assemblée générale annuelle et extraordinaire pour le 15 août 2025. Les actionnaires voteront sur l’élection des administrateurs, la nomination des auditeurs et, notamment, sur un plan visant à distribuer jusqu’à 12 millions d’actions ordinaires de BioGene Therapeutics aux actionnaires de PreveCeutical.
Cette opération conduira les actionnaires à détenir des parts dans deux sociétés distinctes : BioGene, spécialisée dans le développement du programme de thérapie génique double, et PreveCeutical, qui poursuivra son focus sur les thérapies préventives et curatives utilisant des produits biologiques. Cette séparation stratégique vise à élargir la base d’actionnaires des deux entreprises et à améliorer l’accès aux capitaux pour la recherche et le développement.
PreveCeutical Medical (OTCQB: PRVCF) hat seine jährliche Haupt- und Sonderversammlung für den 15. August 2025 angesetzt. Die Aktionäre werden über die Wahl der Direktoren, die Ernennung der Wirtschaftsprüfer und insbesondere über einen Plan abstimmen, bis zu 12 Millionen Stammaktien von BioGene Therapeutics an die PreveCeutical-Aktionäre zu verteilen.
Diese Vereinbarung führt dazu, dass die Aktionäre Anteile an zwei getrennten Unternehmen halten: BioGene, das sich auf die Entwicklung des Dual-Gentherapie-Programms konzentriert, und PreveCeutical, das weiterhin seinen Fokus auf präventive und kurative Therapien mit organischen Produkten legt. Diese strategische Trennung zielt darauf ab, die Aktionärsbasis beider Unternehmen zu erweitern und den Zugang zu Kapital für Forschung und Entwicklung zu verbessern.
- Strategic separation will allow for more focused investment opportunities in specific business segments
- Potential for improved access to capital for both companies' research and development
- Shareholders will maintain ownership in both companies post-distribution
- None.
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be asked to approve:
the election of Stephen Van Deventer, Makarand Jawadekar, Linnéa Olofsson, Kathleen Rokita and C. Evan Ballantyne as directors of the Company;
the ratification of the appointment of Davidson & Company LLP, Chartered Professional Accountants, as the auditors of PreveCeutical for the financial year ending December 31, 2024, and 2025;
a plan of arrangement under the provisions of Division 5 of Part 9 of the Business Corporations Act (British Columbia), pursuant to which the Company will distribute up to 12,000,000 common shares of BioGene Therapeutics Inc. ("BioGene") to the PreveCeutical Shareholders; (the "Arrangement and Distribution") and
the adoption of the PreveCeutical's Omnibus Equity Incentive Plan.
Once the Arrangement and Distribution is complete, the PreveCeutical Shareholders will own shares in two companies: BioGene, which will focus on the development of the Dual Gene Therapy program, and PreveCeutical, which will continue to focus on developing innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical believes that the Arrangement and Distribution is in the best interests of PreveCeutical and the PreveCeutical Shareholders for numerous reasons, including that separating PreveCeutical and BioGene will expand both PreveCeutical's and BioGene's potential shareholder base and access to capital for research, development and clinical trials by allowing investors that want specific ownership in the particular business of BioGene the opportunity to invest directly in BioGene rather than through PreveCeutical.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669 Or
Investor Relations ir@preveceutical.com
Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256761
FAQ
When is PreveCeutical's (PRVCF) annual general meeting scheduled for 2025?
How many BioGene Therapeutics shares will be distributed to PreveCeutical shareholders?
What will be the focus areas of PreveCeutical and BioGene after the separation?
Who are the proposed directors for PreveCeutical's board in 2025?
What is the purpose of PreveCeutical's separation from BioGene Therapeutics?
